Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2025 20:19 ET | Source: Mesoblast Limited

Ryoncil® is Now Available for Purchase in the United States

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil®...
March 13, 2025 19:42 ET | Source: Mesoblast Limited

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing...
March 12, 2025 07:30 ET | Source: Mesoblast Limited

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive...
March 06, 2025 18:54 ET | Source: Mesoblast Limited

Mesoblast Added to S&P/ASX 200 INDEX

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the...
February 26, 2025 17:30 ET | Source: Mesoblast Limited

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and...
February 25, 2025 18:13 ET | Source: Mesoblast Limited

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
February 23, 2025 18:33 ET | Source: Mesoblast Limited

Dr. Gregory George MD PhD Joins Mesoblast Board

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed...
February 13, 2025 18:37 ET | Source: Mesoblast Limited

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently...
January 30, 2025 19:11 ET | Source: Mesoblast Limited

Ryoncil® Commercial Launch Update and Product Pipeline

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...
January 30, 2025 18:20 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right